Back to Trades
Mehta Vimal
CEO and PresidentDirectorCIK 0001733369
Largest Purchase
No open-market purchases in the recent filings.
Profile
- Filings
- 9
- Buy transactions
- 0
- Sell transactions
- 1
- Companies
- 1
- Active
- 2025–2026
Mehta Vimal, CEO and President, Director, has filed 9 SEC reports (2025–2026), all concentrated in BioXcel Therapeutics, Inc. (BTAI), totaling $21.1K in disclosed volume. Weighing $0 bought versus $21.1K sold, the history is heavily weighted toward selling. Data is sourced from official SEC Form 3, 4, and 5 filings.
Associated Companies
Trading History
9 loaded
| Jun 17 | BTAI BioXcel Therapeutics, Inc. | Mehta Vimal | CEO and President, Director | Exercise | $0 |
| May 22 | BTAI BioXcel Therapeutics, Inc. | Mehta Vimal | CEO and President, Director | Sell | $21.1K |
| May 7 | BTAI BioXcel Therapeutics, Inc. | Mehta Vimal | CEO and President, Director | Exercise | $0 |
| Mar 16 | BTAI BioXcel Therapeutics, Inc. | Mehta Vimal | CEO and President, Director | Exercise | $0 |
| Jan 5 | BTAI BioXcel Therapeutics, Inc. | Mehta Vimal | CEO and President, Director | Award | $0 |
| Dec 15 | BTAI BioXcel Therapeutics, Inc. | Mehta Vimal | CEO and President, Director | Exercise | $0 |
| Sep 16 | BTAI BioXcel Therapeutics, Inc. | Mehta Vimal | CEO and President, Director | Exercise | $0 |
| Aug 5 | BTAI BioXcel Therapeutics, Inc. | Mehta Vimal | CEO and President, Director | Award | $0 |
| Jul 22 | BTAI BioXcel Therapeutics, Inc. | Mehta Vimal | CEO and President, Director | Grant | $0 |
9 filings